Roche Holding AG (RHHBY) and Alnylam announced on Tuesday that the Phase II Kardia-2 study of Zilebesiran, an RNAi therapeutic in development for hypertension treatment, successfully met its primary endpoint.
Individuals with mild to moderate hypertension, who were treated with Zilebesiran alongside standard hypertension medication experienced a significant reduction in systolic blood pressure at month three.
The companies plan to present the Kardia-2 study results as a late-breaking abstract at the 2024 American College of Cardiology Annual Scientific Session in April.
The companies have also initiated the global Phase II Kardia-3 study to assess the effectiveness of Zilebesiran in combination with two or more hypertension medications for individuals with uncontrolled hypertension at high cardiovascular risk.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.